BIOCRYST PHARMACEUTICALS INC Logo

BIOCRYST PHARMACEUTICALS INC

Develops oral small-molecule drugs for rare diseases like hereditary angioedema.

BCRX | US

Overview

Corporate Details

ISIN(s):
US09058V1035
LEI:
Country:
United States of America
Address:
4505 EMPEROR BOULEVARD, 27703 DURHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioCryst Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel medicines for rare diseases. The company specializes in creating oral small-molecule and protein therapeutics for patients with significant unmet medical needs, with a primary focus on hereditary angioedema (HAE) and other complement-mediated conditions. Founded in 1986, BioCryst utilizes a structure-guided drug design approach that combines biology, chemistry, and advanced technologies to develop first-in-class or best-in-class treatments. The company's mission is to improve patients' lives by advancing novel therapeutics globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BIOCRYST PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOCRYST PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOCRYST PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT

Talk to a Data Expert

Have a question? We'll get back to you promptly.